A Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19

Explore a 25-minute webinar presented by Julia Han Noll, MS, discussing a Phase 1 trial of Cyclosporine for hospitalized COVID-19 patients. Learn about the potential of Cyclosporine A (CSA) as a treatment option for COVID-19, focusing on its ability to modulate cytokine production and possible antiviral properties against coronaviruses. Discover the results of a study involving 10 hospitalized, oxygen-requiring, noncritically ill patients treated with CSA, including clinical responses, adverse events, and changes in serum cytokines and chemokines associated with COVID-19 hyperinflammation. Gain insights into the safety and feasibility of short courses of CSA in COVID-19 patients requiring oxygen, and its potential as an adjunct treatment in resource-limited healthcare settings. Understand the significant reductions observed in serum cytokines, chemokines, and type I IFN gene expression signatures following CSA administration.

A Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19